Latest hepatitis C Stories

STOCKHOLM, November 1, 2012 /PRNewswire/ -- - Companies to evaluate a two-drug combination of Medivir/Janssen's investigational protease inhibitor simeprevir (TMC435) and Vertex's investigational nucleotide analogue VX-135 - Phase II proof-of-concept study to begin in early 2013 to evaluate safety, tolerability and viral cure rates of 12-week treatment regimen Medivir AB (OMX: MVIR), announced today plans for a phase...

TITUSVILLE, N.J., Nov. 1, 2012 /PRNewswire/ -- Janssen Pharmaceuticals, Inc. today announced that it has entered into a non-exclusive collaboration with Vertex Pharmaceuticals Incorporated to evaluate in a Phase 2 study the safety and efficacy of an all-oral regimen for the treatment of hepatitis C (HCV). The regimen will include Janssen's investigational protease inhibitor simeprevir (TMC435) and Vertex's investigational nucleotide analogue HCV polymerase inhibitor VX-135. As a first...

BOSTON and Alexandria, Va., Oct. 31, 2012 /PRNewswire/ -- AASLD President Guadalupe Garcia-Tsao, MD, will host a press conference on the first full day of presentations at The Liver Meeting®, the annual meeting of the American Association for the Study of Liver Diseases. Dr. Garcia-Tsao will highlight individual studies and themes from the 2047 abstracts to be presented at this year's meeting from the leading researchers in the field. She has selected to review 18 abstracts in...

WATERTOWN, Mass., Oct. 17, 2012 /PRNewswire/ -- Enanta Pharmaceuticals, Inc., a research and development-focused biotechnology company dedicated to creating small molecule drugs in the infectious disease field, announced that Abbott initiated an interferon-free combination Phase 3 clinical trial for hepatitis C (HCV) that included the collaboration's protease inhibitor, ABT-450. This trial was initiated following the release of positive results from the study known as "Aviator",...

RI MUHC study evaluates accuracy and convenience Timely screening and diagnosis is critical to the success of new treatments and ultimately to the survival of hepatitis C patients. A new study led by the Research Institute of the McGill University Health Centre (RI MUHC) is the first to show that hepatitis C rapid and point of care tests with a quick turnaround time are highly accurate and reliable as conventional first-line laboratory tests. This head-to-head analysis, published in the...

ALBANY, New York, October 16, 2012 /PRNewswire/ -- New Market Research Report Added in MarketResearchReports.Biz Reports Database Hepatitis C - Pipeline Review, H2 2012 [http://www.marketresearchreports.biz/analysis/135142 ] Global Markets Directs [http://www.marketresearchreports.biz/publisher/37 ], 'Hepatitis C Pipeline Review [http://www.marketresearchreports.biz/analysis/135142 ], H2 2012', provides an overview of the Hepatitis C therapeutic pipeline. This report...

BEERSE, Belgium, October 16, 2012 /PRNewswire/ -- NOT INTENDED FOR US JOURNALISTS - OPTIMIZE study results to be presented in late-breaking poster presentation at the American Association for the Study of Liver Diseases (AASLD) 2012 show non-inferior sustained virological response (SVR12) rates in previously untreated genotype-1 patients receiving an INCIVO(R) (telaprevir) based regimen twice-daily versus...

BOSTON, Oct. 16, 2012 /PRNewswire/ -- Janssen Research & Development Ireland (Janssen) will present new data on simeprevir (TMC435), an investigational protease inhibitor, in hepatitis C (HCV) patients at the Annual Meeting of the American Association for the Study of Liver Diseases (AASLD), which takes place November 9 to 13 in Boston. "We are pleased that these data have been selected for presentation at the AASLD annual meeting," said Wim Parys, Head of Infectious Diseases,...

ABBOTT PARK Ill., Oct. 15, 2012 /PRNewswire/ -- Abbott (NYSE: ABT) today announced initial results from "Aviator," a phase 2b study of its interferon-free, investigational regimen for the treatment of hepatitis C (HCV). Initial results show sustained virological response at 12 weeks post treatment (SVR12) in 99 percent of treatment-naive (n=77) and 93 percent of null responders (n=41) for genotype 1 (GT1) HCV patients taking a combination of ABT-450/r, ABT-267, ABT-333 and ribavirin...

Says one of fastest growing segments of state economy poses serious health risks HARRISBURG, Pa., Oct. 9, 2012 /PRNewswire-USNewswire/ -- Auditor General Jack Wagner today called on the General Assembly and the state the Department of Health to step up the state's role in regulating the tattoo parlor industry in Pennsylvania because of potential health risks to the general public, including Hepatitis C. Wagner said that requiring Pennsylvania's more than 750 known tattoo parlors and...